Operating cash flow of -$70.2M in 2026Q2 and zero dividends or buybacks indicate persistent cash burn with no internal funding source, suggesting the company may depend on external capital to sustain operations.
Zentalis Pharmaceuticals, Inc. (ZNTL) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -166.79M | -125.25M | -170.86M | -207.82M | -163.75M | -154.09M | -86.83M | -39.14M | -24.25M |
| Operating CF Margin % | - | - | -253.41% | - | - | - | - | - | -173221.43% |
| Operating CF Growth % | -102.45% | 26.7% | 17.79% | -26.91% | -6.27% | -77.48% | -121.81% | -61.41% | - |
| Net Income | -141.67M | -137.06M | -165.87M | -292.19M | -237.11M | -166.09M | -118.55M | -46.38M | -23.43M |
| Depreciation & Amortization | 613K | 739K | 1.29M | 1.39M | 1.43M | 544K | 160K | 111K | 51K |
| Stock-Based Compensation | 12.75M | 20.72M | 67.27M | 54.82M | 46.84M | 35.74M | 23.15M | 617K | 308K |
| Deferred Taxes | 0 | 0 | 0 | -853K | -769K | -2.51M | 17K | 0 | 2.37M |
| Other Non-Cash Items | 5.08M | -526K | -57.01M | 23.15M | 12.61M | -38.38M | 556K | 0 | -2.37M |
| Working Capital Changes | -8.21M | -9.12M | -16.54M | 5.86M | 13.25M | 16.61M | 7.84M | 6.51M | -1.18M |
| Change in Receivables | 0 | 5M | -5M | 0 | 0 | 413K | -277K | 777K | -254K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -5.52M | 0 | -1.86M |
| Change in Payables | -7.58M | -17.32M | -18.02M | 10.92M | 15.53M | 13.96M | 14.31M | 7.12M | 977K |
| Cash from Investing | 67.19M | 131.62M | 176.56M | -44.46M | -114.18M | -18.11M | -284.83M | -352K | -227K |
| Capital Expenditures | -68K | 0 | -221K | -583K | -2.55M | -6.11M | -758K | -352K | -227K |
| CapEx % of Revenue | - | - | 0.33% | - | - | - | - | - | 1621.43% |
| Acquisitions | 569K | 0 | 65K | 0 | 111.63K | -14.32M | 18.42M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -440K | 698K | 0 | 0 | -111.63K | 0 | -18.42M | 0 | 0 |
| Cash from Financing | 80.49M | -4.28M | 108K | 237.3M | 261.04M | 178.52M | 360.44M | 81.83M | 9.47M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 83.4M | -4.28M | 349K | 237.3M | 261.04M | 179.67M | 342.01M | 81.88M | 9.47M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -2.91M | 0 | -241K | 0 | 0 | -1.15M | 18.42M | -46K | 0 |
| Net Change in Cash | -19.11M | 2.09M | 5.81M | -14.98M | -16.89M | 6.31M | -11.22M | 42.34M | -15.01M |
| Free Cash Flow | -166.86M | -125.25M | -171.08M | -208.41M | -166.3M | -160.2M | -87.58M | -39.49M | -24.48M |
| FCF Margin % | - | - | -253.74% | - | - | - | - | - | -174842.86% |
| FCF Growth % | -24.52% | 26.79% | 17.91% | -25.32% | -3.81% | -82.91% | -121.76% | -61.35% | - |
| FCF per Share | -1.97 | -1.74 | -2.41 | -3.19 | -3.15 | -3.75 | -2.13 | -1.10 | -1.36 |
| FCF Conversion (FCF/Net Income) | 1.18x | 0.91x | 1.03x | 0.71x | 0.69x | 0.97x | 0.74x | 0.86x | 1.15x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 359K | 140K | 12K | 20K | 18K | 15K | 4K |
Quick answers to the most common questions about buying ZNTL stock.
Zentalis Pharmaceuticals, Inc. (ZNTL) generated $-125.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported negative free cash flow of $125.2M in 2025, indicating capital requirements exceeded cash from operations.
Zentalis Pharmaceuticals, Inc. (ZNTL) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Losses Mirror Operating Cash Burn
Based on reported quarterly figures, ZNTL's operating cash flow has tracked net losses closely, with OCF/NI ratios mostly between 0.68 and 1.29 across recent quarters, indicating losses are largely cash-based rather than accrual-driven.
The ratio of operating cash flow to net income sits near 0.9 in the latest quarters, which suggests reported losses are predominantly real cash outflows rather than non-cash charges. The 2024Q1 positive net income of $10.1M alongside a -$52.0M operating cash outflow, however, illustrates how earnings can diverge sharply from cash in individual periods. Investors should monitor whether this near-parity persists, as it leaves little accounting cushion against the ongoing burn.
Free Cash Flow Deeply Negative Throughout
As reported in the quarterly data, ZNTL's free cash flow ranged from -$70.2M in 2026Q2 to -$27.0M in 2025Q3, with no period showing positive FCF across the ten quarters provided.
Free cash flow has remained negative in every reported quarter, and the most recent figure of -$70.2M represents the sharpest outflow in the series, roughly double the prior quarter. Because no revenue is reported in recent periods, FCF margin cannot be meaningfully computed, so the trajectory must be judged on absolute burn. This pattern suggests the company's funding requirement is continuous and may warrant further investigation into the runway implied by current cash reserves.
Negligible Capital Intensity Profile
Based on reported figures, ZNTL's capital expenditures were minimal, at or near zero in most quarters and never exceeding $181K, indicating a capital-light operating model.
Capex has been virtually absent, with the only nonzero entries being small outflows in 2024Q1 and 2024Q2 and a $34K charge in the two most recent quarters. Depreciation and amortization of roughly $150K to $330K per quarter aligns with this light asset base. The low capital intensity suggests the cash burn is driven by operating expenses, primarily research and development, rather than by investment in physical infrastructure.
No Shareholder Returns Amid Burn
According to the reported cash flow statements, ZNTL paid no dividends and executed no share repurchases across all ten quarters, with acquisition outflows appearing only sporadically and in small amounts.
The absence of dividends and buybacks is consistent with a company consuming cash to fund development rather than returning it. Acquisition activity appears limited to small figures such as $569K and $564K, which do not materially affect the overall deployment picture. Capital allocation therefore reflects a single priority, sustaining operations, and any future capital raise would likely be directed toward that same use.
Stock Compensation Masks True Cost
Based on reported figures, stock-based compensation reached $31.4M in 2024Q4 and $6.4M in 2026Q2, meaning a portion of the operating cost base is non-cash and may understate economic dilution.
Adding back stock-based compensation to operating cash flow would still leave the company deeply cash-negative, so the core burn conclusion holds regardless. However, the non-cash equity cost represents real dilution borne by existing shareholders that does not appear in free cash flow. Analysts should weigh per-share economics rather than cash burn alone when assessing the true cost of the current operating structure.